CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

21-073/S012

Trade Name: Actos Tablets 15mg, 30mg, 45mg

Generic Name: (pioglitazone HCL)

Sponsor: Takeda Pharmaceuticals of North America, Inc

Approval Date: May 5, 2001

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-073/S012

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-073/S012

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-073/S-012

Takeda Pharmaceuticals North America, Inc.
Attention: Robert M. Pilson, R.Ph.
Manager, Regulatory Compliance
475 Half Day Road, Suite 500
Lincolnshire, IL 60069

Dear Mr. Pilson:

Please refer to your supplemental new drug application dated May 9, 2001, received May 10, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Actos® (pioglitazone hydrochloride) Tablets, 15 mg, 30 mg, and 45 mg.

This supplemental new drug application provides for the addition of [redacted] as an analytical testing facility for the drug substance and drug product.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at (301) 827-6422.

Sincerely,

{See appended electronic signature page}

Stephen K. Moore, Ph.D.
Chemistry Team Leader I, for
Division of Metabolic and Endocrine Drug Products,
(HFD-510)
DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Stephen Moore
5/22/01 03:13:39 PM

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-073/S012

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW

Organization CDER/HFD-510 Division of Metabolism and Endocrine Drug Products	**NDA # 21-073** Approved: 21-JUL-1999
Name and Address of Applicant: Takeda Pharmaceuticals America Inc. 101 Carnegie Center, Suite 207 Princeton, NJ 08540 Phone: (609) 452-1113 x-4409 Fax: (609) 452-1218	**Supplement** SCM-012 Doc. 09-MAY-2001 Rec. 10-MAY-2001 **Name Of The Drug** Actos™ Tablets **Nonproprietary Name** Pioglitazone Hydrochloride Tablets
Supplement provides for the addition of [redacted] as an analytical testing facility for the drug substance and drug product.	**Amendment(s)** --

Pharmacological Category:	**How Dispensed**	**Supporting Documents**
Hypoglycemic Agent, treatment of NIDDM.	Oral Rx	--
Dosage Form Tablets	**Potencies** 15-, 30- and 45-mg	

Chemical Name and Structure

Pioglitazone

$C_{19}H_{20}N_2O_3S \cdot HCl$
MW = 356.43 + 36.57 = 392.90



(±)-5[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione monohydrochloride

Comments: This Supplement –Changes Being Effected in 30 days- provides for the addition of [redacted] as an [redacted] facility for pioglitazone and Actos® Tablets. [redacted] is in compliance with cGMP as certified by the firm itself in the application, and corroborated by the Office of Compliance (EER dated 14-MAY-2001 attached). The firm, Takeda pharmaceuticals America Inc., certifies that the tests methods approved in NDA 21-073 have been transferred to [redacted] utilizing an approved Transfer Protocol and no post approval commitments have been made by the applicant relating to the [redacted]. *Adequate information has been provided, and all regulatory requirements -Post Approval Changes –Analytical Testing Laboratory Sites (PAC-ATLS)- have been fulfilled.*

Conclusions and Recommendations: [redacted] has been found acceptable for the analytical testing of the drug substance, pioglitazone, and the drug product, Actos® (Pioglitazone) Tablets. From the chemistry point of view, this supplement can be approved. **Issue approval letter.**

Reviewer Name (and signature) **Date Completed:** 14-MAY-2001

Xavier Ysern, PhD

R/D Init.

filename: /nda/21073s12.doc

DISTRIBUTION: Original: NDA 21-073 cc: HFD-510 Division File/ JWeber / SMoore/ XYsern

CBE - 30 days

AP

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Application: NDA 21073/012
Priority: 1P
Org Code: 510
Stamp: 10-MAY-2001 Regulatory Due: 10-SEP-2001
Action Goal:
District Goal: 06-AUG-2001
Applicant: TAKEDA PHARMS
475 HALF DAY RD STE 500
LINCOLNSHIRE, IL 60069
Brand Name: ACTOS (PIOGLITAZONE HCL)15/30/45MG TABS
Established Name:
Generic Name: PIOGLITAZONE HCL
Dosage Form: TAB (TABLET)
Strength: 15-, 30- AND 45-MG

FDA Contacts:			
	J. WEBER	(HFD-510)	301-827-6422 , Project Manager
	X. YSERN	(HFD-510)	301-827-6420 , Review Chemist
	S. MOORE	(HFD-510)	301-827-6430 , Team Leader

Overall Recommendation:

ACCEPTABLE on 14-MAY-2001 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: [redacted]
DMF No:
AADA No:

Profile: CTL OAI Status: NONE
Last Milestone: OC RECOMMENDATION
Milestone Date: 14-MAY-2001
Decision: ACCEPTABLE
Reason: BASED ON PROFILE
Responsibilities: [redacted]

Establishment: [redacted]
DMF No:
AADA No:

Profile: CTL OAI Status: NONE
Last Milestone: OC RECOMMENDATION
Milestone Date: 14-MAY-2001
Decision: ACCEPTABLE
Reason: BASED ON FILE REVIEW
Responsibilities: [redacted]

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Xavier Ysern
5/17/01 10:49:11 AM
CHEMIST

AP

Stephen Moore
5/18/01 09:13:28 AM
CHEMIST